S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
The "Smart Money" Is Ready for May 1st Are You? (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
He Is Giving Away Bitcoin (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
The “Perfect Storm” for Gold (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
The "Smart Money" Is Ready for May 1st Are You? (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
He Is Giving Away Bitcoin (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
The “Perfect Storm” for Gold (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
The "Smart Money" Is Ready for May 1st Are You? (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
He Is Giving Away Bitcoin (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
The “Perfect Storm” for Gold (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
The "Smart Money" Is Ready for May 1st Are You? (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
He Is Giving Away Bitcoin (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
The “Perfect Storm” for Gold (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
Free Trial
NASDAQ:OPHT

IVERIC bio (OPHT) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)
Free OPHT Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$1.13
▼
$1.39
52-Week Range
N/A
Volume
N/A
Average Volume
159,109 shs
Market Capitalization
$1.65 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
OPHT stock logo

About IVERIC bio Stock (NASDAQ:OPHT)

IVERIC bio, Inc. is a biopharmaceutical company which engages in discovering, developing, and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in New York, NY.

OPHT Stock News Headlines

November 5, 2023 | morningstar.com
Gossamer Bio Inc GOSS
June 30, 2023 | msn.com
Iveric Bio ticks higher as it sees sale to Astellas closing July 11
April 18, 2024 | Crypto 101 Media (Ad)
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
June 29, 2023 | msn.com
Iveric Bio falls amid concern about Astellas deal
May 6, 2023 | msn.com
Baird Downgrades IVERIC bio (ISEE)
May 6, 2023 | msn.com
Apellis Pharmaceuticals: Maintain 'Buy' Following Astellas' $5.9 Billion Acquisition Of Iveric Bio
May 2, 2023 | msn.com
Iveric Bio (NASDAQ:ISEE) Sold for $5.9B
May 1, 2023 | msn.com
Astellas to Buy Eye-Drug Maker Iveric Bio for $5.9 Billion
April 18, 2024 | Gold Safe Exchange (Ad)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
May 1, 2023 | reuters.com
Astellas Pharma buys Iveric Bio for $5.9 billion
April 30, 2023 | msn.com
Astellas Pharma to Buy Iveric Bio for $5.9 Billion
April 30, 2023 | wsj.com
Astellas Pharma to Buy Iveric Bio for About $5.9B
April 30, 2023 | msn.com
Astellas Pharma agrees to buy Iveric Bio for $5.9 Billion
March 3, 2023 | markets.businessinsider.com
Robert W. Baird Keeps Their Buy Rating on Iovance Biotherapeutics (IOVA)
March 1, 2023 | marketwatch.com
IVERIC Bio Shares Up 14% After Positive Trial Results, 4Q Losses
February 17, 2023 | marketwatch.com
Iveric Bio Shares Rise 16% After FDA Accepts New Drug App for Avacincaptad Pegol
February 16, 2023 | nasdaq.com
Deep Track Capital Now Owns 5.88% of IVERIC bio (ISEE)
February 16, 2023 | nasdaq.com
Rtw Investments Now Owns 0.60% of IVERIC bio (ISEE)
September 16, 2022 | seekingalpha.com
ISEE IVERIC bio, Inc.
September 7, 2022 | markets.businessinsider.com
Where IVERIC bio Stands With Analysts
August 25, 2022 | markets.businessinsider.com
Iveric Bio To Announce GATHER2 Trial Data In September
January 18, 2022 | thestreet.com
Why Ophthotech (OPHT) Stock Is Surging Today
August 9, 2021 | seekingalpha.com
IVERIC bio, Inc. 2021 Q2 - Results - Earnings Call Presentation
See More Headlines
Receive OPHT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IVERIC bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/31/2018
Today
4/18/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:OPHT
CUSIP
N/A
CIK
1410939
Web
www.ophthotech.com
Phone
(212) 845-8200
Fax
N/A
Employees
35
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($1.67)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$63.09 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-141.53%
Return on Assets
-41.88%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
10.09
Quick Ratio
10.09

Sales & Book Value

Annual Sales
$209.98 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.00 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
41,420,000
Free Float
N/A
Market Cap
$1.65 billion
Optionable
Optionable
Beta
1.49
The Best High-Yield Dividend Stocks for 2024 Cover
The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Glenn P. Sblendorio
    President, Chief Executive Officer & Director
  • Keith Westby
    Chief Operating Officer & Senior Vice President
  • David F. Carroll
    Chief Financial Officer, Treasurer & SVP
  • Kourous A. Rezaei
    Chief Medical Officer & Senior Vice President
  • Abraham Scaria
    Chief Scientific Officer

Key Competitors

View All Competitors

OPHT Stock Analysis - Frequently Asked Questions

How were IVERIC bio's earnings last quarter?

IVERIC bio, Inc. (NASDAQ:OPHT) released its quarterly earnings data on Wednesday, October, 31st. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.43) by $0.02.

What other stocks do shareholders of IVERIC bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IVERIC bio investors own include iShares Preferred and Income Securities ETF (PFF), Puma Biotechnology (PBYI), Incyte (INCY), Apollo Investment (AINV), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), Gilead Sciences (GILD), Nektar Therapeutics (NKTR), Bausch Health Companies (BHC).

This page (NASDAQ:OPHT) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
SHOCKING Crypto Leak…
Crypto 101 Media
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
Biden replacement revealed?
Paradigm Press
He Is Giving Away Bitcoin
Crypto Swap Profits
The #1 Crypto for 2024
InvestorPlace
How Biden has already won 2024
Porter & Company